PT  - JOURNAL ARTICLE
AU  - Martin Pavelka
AU  - Kevin Van-Zandvoort
AU  - Sam Abbott
AU  - Katharine Sherratt
AU  - Marek Majdan
AU  - CMMID COVID-19 working group
AU  - Inštitút Zdravotných Analýz
AU  - Pavol Jarčuška
AU  - Marek Krajčí
AU  - Stefan Flasche
AU  - Sebastian Funk
TI  - The impact of population-wide rapid antigen testing on SARS-CoV-2 prevalence in Slovakia
AID  - 10.1101/2020.12.02.20240648
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.12.02.20240648
4099  - http://medrxiv.org/content/early/2021/03/02/2020.12.02.20240648.short
4100  - http://medrxiv.org/content/early/2021/03/02/2020.12.02.20240648.full
AB  - Slovakia conducted multiple rounds of population-wide rapid antigen testing for SARS-CoV-2 in late 2020, combined with a period of additional contact restrictions. Observed prevalence decreased by 58% (95% CI: 57-58%) within one week in the 45 counties that were subject to two rounds of mass testing, an estimate that remained robust when adjusting for multiple potential confounders. Adjusting for epidemic growth of 4.4% (1.1-6.9%) per day preceding the mass testing campaign, the estimated decrease in prevalence compared to a scenario of unmitigated growth was 70% (67-73%). Modelling suggests that this decrease cannot be explained solely by infection control measures, but requires the additional impact of isolation as well as quarantine of household members of those testing positive.Competing Interest StatementMartin Pavelka is employed as epidemiologist and health data analyst at the Slovak Ministry of Health but had no involvement in the design of the Mass Testing campaigns. Marek Krajči is the current Slovak Minister of Health and was involved in the design of the Mass Testing campaigns. Sebastian Funk advises the UK government as a member of the Scientific Pandemic Influenza Group on Modelling (SPI-M) in an unpaid role. All other authors declare that they have no conflicts of interest.Funding StatementMartin Pavelka is employed by the Slovak Ministry of Health. Marek Krajči is a medical doctor, member of the Slovak government and Slovak Minister of Health. Stefan Flasche is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant number 208812/Z/17/Z). Sebastian Funk, Sam Abbott and Katharine Sherratt are supported by the Wellcome Trust (210758/Z/18/Z). KvZ is supported by Elrha's Research for Health in Humanitarian Crises (R2HC) Programme, which aims to improve health outcomes by strengthening the evidence base for public health interventions in humanitarian crises. The R2HC programme is funded by the UK Government (DFID), the Wellcome Trust, and the UK National Institute for Health Research (NIHR). The following funding sources are acknowledged as providing funding for the working group authors. BBSRC LIDP (BB/M009513/1: DS). This research was partly funded by the Bill & Melinda Gates Foundation (INV-001754: MQ; INV-003174: KP, MJ, YL; NTD Modelling Consortium OPP1184344: CABP, GFM; OPP1180644: SRP; OPP1183986: ESN). BMGF (OPP1157270: KA). DFID/Wellcome Trust (Epidemic Preparedness Coronavirus research programme 221303/Z/20/Z: CABP). EDCTP2 (RIA2020EF-2983-CSIGN: HPG). ERC Starting Grant (#757699: MQ). This project has received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (101003688: KP, MJ, PK, RCB, WJE, YL). This research was partly funded by the Global Challenges Research Fund (GCRF) project 'RECAP' managed through RCUK and ESRC (ES/P010873/1: AG, CIJ, TJ). HDR UK (MR/S003975/1: RME). MRC (MR/N013638/1: NRW). Nakajima Foundation (AE). This research was partly funded by the National Institute for Health Research (NIHR) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care (16/136/46: BJQ; 16/137/109: BJQ, FYS, MJ, YL; Health Protection Research Unit for Immunisation NIHR200929: NGD; Health Protection Research Unit for Modelling Methodology HPRU-2012-10096: TJ; NIHR200908: RME; NIHR200929: FGS, MJ; PR-OD-1017-20002: AR, WJE). Royal Society (Dorothy Hodgkin Fellowship: RL; RP\EA\180004: PK). UK DHSC/UK Aid/NIHR (PR-OD-1017-20001: HPG). UK MRC (MC_PC_19065 - Covid 19: Understanding the dynamics and drivers of the COVID-19 epidemic using real-time outbreak analytics: AG, NGD, RME, SC, TJ, WJE, YL; MR/P014658/1: GMK). Authors of this research receive funding from UK Public Health Rapid Support Team funded by the United Kingdom Department of Health and Social Care (TJ). Wellcome Trust (206250/Z/17/Z: AJK, TWR; 206471/Z/17/Z: OJB; 208812/Z/17/Z: SC; 210758/Z/18/Z: JDM, JH, NIB, SA, SRM). No funding (AMF, AS, CJVA, DCT, JW, KEA, YWDC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Only publicly available data was used and therefore no exemption necessary.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDaily incidence of positive COVID-19 test reports and the results of the mass testing are available through governmental websites and included in the code repository. All analyses were conducted in R and can be found at www.github.com/sbfnk/covid19.slovakia.mass.testing (data analyses) and https://github.com/kevinvzandvoort/covid_svk (simulation model).https://www.github.com/sbfnk/covid19.slovakia.mass.testing